Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06146920 · ClinicalTrials.gov registry record · NA
Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation
A NA study of Non-Small Cell Lung Cancer and Melanoma, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- NA
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT06146920 is a NA study of Non-Small Cell Lung Cancer and Melanoma that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 39 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06146920, a NA study of Non-Small Cell Lung Cancer and Melanoma, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this prospective study to investigate the use of circulating tumor DNA (ctDNA) to guide end of therapy decisions in patients with melanoma or non-small-cell lung cancer. The main question it aims to answer is: • Do patients with metastatic melanoma or non-small-cell lung cancer, who have received at least 12 months of immune checkpoint inhibition (monotherapy or in combination) with evidence of disease response/control on imaging and have no evidence of circulating tumor DNA, have an increased 12-month disease free survival in comparison to historical controls?
Conditions Studied
Interventions
- OTHER Evaluation of ctDNA using the F1T after 1 year of immunotherapy
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2024-01-10 |
| Est. Completion | 2028-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06146920
The ClinicalTrials.gov registry entry for NCT06146920 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Evaluation of ctDNA using the F1T after 1 year of immunotherapy is the first listed.
NCT06146920 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06146920 about?
NCT06146920 is a clinical study titled "Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation". The goal of this prospective study to investigate the use of circulating tumor DNA (ctDNA) to guide end of therapy decisions in patients with melanoma or non-small-cell lung cancer. The main question it aims to answer is: • Do patients with metastatic melanoma or non-small-cell lung cancer, who ha...
What is the current status of trial NCT06146920?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 39 participants. The study started on 2024-01-10. Estimated completion is 2028-11.
What conditions does trial NCT06146920 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Melanoma.
What interventions are being tested in trial NCT06146920?
The interventions under investigation include: Evaluation of ctDNA using the F1T after 1 year of immunotherapy (OTHER).
Who is sponsoring clinical trial NCT06146920?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06146920 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dyadic Yoga Program for Patients Undergoing Thoracic Radiotherapy and Their Family Caregivers: The Testing of a Mobile Application Delivery
RECRUITING · NA
-
High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial)
RECRUITING · NA
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
Promoting Immunotherapy Efficacy With Low-Dose Liver RT
RECRUITING · NA
-
Exercise as Maintenance Therapy in Advanced Lung Cancer
RECRUITING · NA
-
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.